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Alopecia areata (AA) is a suspected hair follicle specific autoimmune disease. The potential for cell transfer of AA
using the C3H/HeJ mouse model was examined. Cells isolated from lymph nodes and spleens of AA-affected mice
using magnetic bead conjugated monoclonal antibodies were subcutaneously injected into normal C3H/HeJ re-
cipients. Within 5 wk, all CD8þ cell-injected mice exhibited localized hair loss exclusively at the site of injection that
persisted until necropsy. In contrast, some CD4þ and CD4þ /CD25 cell-injected mice developed extensive, sys-
temic AA, and a combination of CD8þ and CD4þ /CD25 cells injected yielded the highest frequency of systemic AA
induction. CD4þ /CD25þ cells were less able to transfer the disease phenotype, partially blockaded systemic AA
induction by CD4þ /CD25 cells, and prevented CD8þ cell-induced, injection site-localized hair loss. CD11cþ and
CD19þ cells failed to promote significant phenotype changes. Increases in co-stimulatory ligands CD40 and CD80,
plus increased leukocyte apoptosis resistance with reduced CD95, CD95L, and CD120b expression, were asso-
ciated with successful alopecia induction. The results suggest that CD8þ cells may be the primary instigators of
the hair loss phenotype. However, systemic disease expression fate is, apparently determined by CD4þ /CD25
cells, while CD4þ /CD25þ lymphocytes may play a predominantly regulatory role.
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Alopecia areata (AA) is a suspected autoimmune disease
where the clinical hair loss phenotype is believed to be in-
duced by an inflammatory infiltrate, predominantly com-
prising CD4þ and CD8þ lymphocytes, focused on anagen
stage hair follicles. Although much circumstantial evidence
is consistent with this claim, parameters to define AA as a
true autoimmune disease have yet to be fulfilled (McElwee
et al, 1999b). A key requirement of Koch’s postulates, as
adapted to autoimmune disease, states that autoantibodies
and/or autoreactive T cells are the presumed instigators of
autoimmunity. The transfer of these factors to susceptible
animals should lead to induction of the autoimmune disease
(Rose and Bona, 1993). Intriguingly, two case reports sug-
gest that AA might be transferred between humans by bone
marrow transplantation (Barahmani et al, 2003; Sanli et al,
2004).
In other autoimmune disease models, transfer of the
disease from affected to unaffected individuals using cell
subsets derived from the immune system has helped define
pathogenic mechanisms involved. Most commonly, CD4þ
(T helper, Th) lymphocytes have been identified as the pri-
mary pathogenic cell subset retaining the ability to transfer
many autoimmune diseases, but other subsets including
CD8þ cells have also been identified as important in dis-
ease pathogenesis (Miller et al, 1988; Mikecz et al, 1990;
Taylor et al, 1995; Petrow et al, 1996; Wong et al, 1996;
Ablamunits et al, 1999; Mora et al, 1999; Huseby et al,
2001). In addition, regulatory cell subsets from the CD4þ
population, particularly CD4þ /CD25þ cells, have been
characterized with key roles in determining an individual’s
autoimmune disease susceptibility (Suri-Payer et al, 1998;
Levings et al, 2001; Shevach, 2002). Cell subset transfer
models of autoimmune disease reveal a complex interplay
between pathogenic and regulatory cells of the immune
system that defines the disease (Sakaguchi et al, 1995;
Suri-Payer et al, 1998; McHugh and Shevach, 2002).
In rodent models for AA, depletion of CD4þ or CD8þ
cells using monoclonal antibodies (mAb) has demonstrated
that these cell subsets are fundamentally required for the
perpetuation of the disease state and removal of one or the1These authors contributed equally to this work.
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other subset enables hair regrowth (McElwee et al, 1996,
1999a; Carroll et al, 2002). Human AA-affected, skin-de-
rived cells have been shown to reinduce inflammatory hair
loss in xenografts of previously AA-affected skin grafted to
scid/scid mice (Gilhar and Krueger, 1987; Gilhar et al, 1998).
Separation of CD4þ and CD8þ cell subsets and their
transfer to this model suggested each cell type alone was
not capable of reinducing hair loss, but in combination hair
loss redeveloped (Gilhar et al, 2002). These studies suggest
that the immune system and lymphocytes in particular are
of primary importance in AA pathogenesis.
Using the C3H/HeJ mouse model for AA (Sundberg et al,
1994), we examined the potential for CD4þ , CD4þ /CD25,
CD8þ , CD19þ (predominantly B cell), and CD11cþ (pre-
dominantly dendritic cell) cell subsets derived from AA-
affected mice to transfer the disease phenotype to
unaffected, immunocompetent mice. We also examined the
potential for the CD4þ /CD25þ candidate regulatory cell
subset to blockade alopecia initiated by CD4þ and CD8þ
cell transfer. The cell subset recipients were examined by
histology and flow cytometry to characterize the injected
cell host’s response and to differentiate between mice that
developed AA and those that did not.
Results and Discussion
As predicted by previous studies (Carroll et al, 2002), the
comparative control groups injected with unseparated
lymph node cells derived from normal haired, and AA-af-
fected donor mice yielded no AA development and a sys-
temic AA expression frequency of 80%, respectively (Table
I). The high frequency of AA development in the group re-
ceiving cells obtained from AA-affected mice indicates that
all adult C3H/HeJ mice are readily susceptible to AA de-
velopment.
CD8þ cells confer localized hair loss whereas CD4þ /
CD25 cells promote systemic AA In this study, all 10
recipients that received subcutaneous injections of CD8þ
cells alone developed localized hair loss at the site of cell
injection, but no hair loss elsewhere, first observed 3–5 wk
after injection and persisting until necropsy at 20 wk post-
injection (Table I) (Fig 1a). Only one CD8þ cell-injected
mouse developed systemic AA with hair loss beyond the
cell injection site, a statistically insignificant frequency of
systemic AA development (p¼0.33). This suggests that
activated CD8þ cells are capable of targeting hair follicles
and are likely the primary mediators of actual hair loss in the
pathogenic disease mechanism. However, in the absence of
other primed immune cell subsets, CD8þ cells alone are
largely unable to activate the immune mechanisms required
for systemic AA development beyond the cell injection site.
This has implications for our understanding of how AA is
perpetuated and spreads. In and of itself, hair follicle dis-
ruption by CD8þ cells is apparently not enough to elicit a
systemic immune response, which also implies that the AA
autoantigen is not created/deliberated solely by the de-
struction of anagen hair follicles.
Compared with mice receiving CD8þ cells alone, rela-
tively little or no hair loss localized at the site of injection
was observed after injection of CD4þ or CD4þ /CD25 cells
(Table I). In contrast, a single subcutaneous injection of
CD4þ cells promoted the development of systemic AA, that
is AA beyond the immediate site of cell injection, in three of
10 (30%) naive hosts. With further purification of the cell
subset to remove CD4þ /CD25þ cells and isolate CD4þ /
CD25 cells for injection, the frequency of systemic AA in-
duction after injection was increased. Seven weeks after
injection, 18 of 23 mice receiving CD4þCD25 cells
showed signs of systemic AA, although the alopecia patch-
es were small. At 20 wk post-injection, eight mice that had
hair loss at 7 wk had apparently recovered from the inflam-
matory insult and alopecia was no longer visible anywhere,
but for 10 of 23 recipients (43%) the AA had become ex-
tensive and covered more than 50% of their total skin area
(Fig 1b), a statistically significant expression frequency
(p¼0.0007).
That there was little or no circumscribed hair loss at the
site of cell injection suggests that CD4þ cells do not directly
contribute to inducing hair loss in the absence of other ac-
tivated cell subsets. But the CD4þ cell population was ca-
pable of inducing a systemic response and induction of
extensive alopecia beyond the site of cell injection, dem-
onstrating that these cells are key mediators of systemic AA
pathogenesis. The systemic development of AA in the rel-
ative absence of hair follicle disruption localized to the site
of cell injection also implies that the AA autoantigen is nat-
urally presented. Further, as the majority (80%) of mice
receiving CD4þCD25 cells developed early signs of sys-
temic AA at 7 wk (but AA was only seen in 43% at necropsy,
20 wk postinjection), we assume that early signs of AA may
have been because of transferred, activated Th cells and
that the amount of naturally presented autoantigen may not
have been sufficient in all mice to fully reactivate memory
T cells. Of eight mice receiving CD4þ /CD25 cells in com-
bination with CD8þ cells (Table I), five developed alopecia
localized at the site of injection and these same mice sub-
sequently developed systemic AA beyond the injection site
that persisted until necropsy. The frequency of systemic
AA development was statistically significantly above that
observed with injection of CD4þ /CD25 cells alone (p¼
0.004). The increased frequency of persistent, systemic AA
development with a combined injection of CD4þ /CD25
and CD8þ cells suggests a synergistic activity of these cells
types in AA pathogenesis.
CD4þ T cells are capable of interaction with major his-
tocompatibility complex (MHC) class II-expressing antigen-
presenting cells (APC), leading to production of interleukin
(IL)-2 and enhancement of APC ability to activate other im-
mune system components, particularly CD8þ cells, through
presentation of antigen in context with MHC class I (Ridge
et al, 1998; Schoenberger et al, 1998; Belz et al, 2002). The
enhancement of APC activity by CD4þ cells is predomi-
nantly mediated by CD40–CD40L interaction and is char-
acterized by upregulation of co-stimulatory receptors
CD80/CD86 and IL-12 production (Cella et al, 1996; Grew-
al et al, 1996). Previously, flow cytometry and microarray
studies demonstrated AA developed in association with in-
creased expression of all these factors (Carroll et al, 2002;
McElwee et al, 2002; Zo¨ller et al, 2002). The interaction of a
host APC with injected, AA antigen-specific CD4þ T cells
may stimulate naive, endogenous CD8þ cytotoxic T cells,
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which may then function as specific effector cells and target
hair follicles. Much the same mechanism has been shown to
occur in tumor targeting by the immune system. Transfer of
tumor antigen-specific CD4þ cells successfully elicits a
CD8þ cell targeting of the tumor via APC activation (Sur-
man et al, 2000).
CD19þ and CD11cþ cells fail to promote hair
loss Transfer of CD19þ cells, predominantly a marker for
B cells, and CD11c primarily expressed on dendritic cells,
candidate APC, each failed to transfer a localized or sys-
temic AA phenotype. Histology and immunohistology of
CD19þ and CD11cþ cell recipient mice failed to demon-
strate any significant differential activity in the skin as com-
pared with controls (data not shown). For CD11cþ cells,
this may seem surprising. The most likely explanation would
be that there were too few AA autoantigen-loaded APC in
the draining lymph nodes that were used for the transfer.
Alternatively, the APC derived from the draining LNC no
longer displayed a migratory phenotype. That CD19þ B
cells were unable to transfer AA is less surprising. Although
production of hair follicle-specific antibodies by B cells can
be identified in the C3H/HeJ mouse model (Tobin et al,
1997), this production is likely to be secondary to a primary,
cell-mediated perturbation of hair follicles (Carroll et al,
2002). This does not, however, render B cells and antibody
production irrelevant to the progression of AA. Autoanti-
bodies may have a secondary role in disease exacerbation
and activated B cells can play an APC role (Serreze et al,
1998).
CD4þ /CD25þ cells can regulate AA Transfer of CD4þ /
CD25þ cells has been shown to prevent autoimmune dis-
ease in several models (Sakaguchi et al, 1995; Suri-Payer
et al, 1998) and we sought to examine the potential of
CD4þ /CD25þ cells to modulate AA development. The de-
pressed frequency of CD4þ /CD25þ cells in AA-affected
mice (Zo¨ller et al, 2002) significantly limited the availability of
cells for use in AA transfer studies. However, of the 12 mice
injected with CD4þ /CD25þ cells alone, 10 failed to develop
localized or systemic AA over 20 wk until necropsy. Two did
develop systemic AA very late at 18 wk post-injection. Al-
though cells with constituent CD4þ /CD25þ expression are
purportedly regulatory cells, it is likely there are some CD4þ
pathogenic cells with an induced CD25þ expression within
the CD4þ /CD25þ population derived from mice with overt
AA. This may account for the transfer of AA in two mice.
Overall, however, the relative lack of AA induction and the
late induction of hair loss in those mice that did develop
overt AA is consistent with the hypothesis that CD4þ /
CD25þ cells are candidate regulatory cells. Most signifi-
cantly, co-transfer of CD4þ /CD25þ cells with CD4þ /
CD25 cells or CD8þ cells apparently prohibited the hair
loss patterns seen with these pathogenic cell subsets when
injected alone (Fig 1c, d). All five mice injected with CD8þ
and CD4þ /CD25þ cells failed to present large areas of hair
loss at the injection site, nor did they develop systemic AA.
Similarly, none of the 10 mice injected with CD4þ /CD25þ
cells plus CD4þ /CD25 cells developed overt alopecia, a
result that approached statistical significance (p¼0.0148).
Boosting the activity or increasing the numbers of CD4þ /
CD25þ cells has been suggested as one approach in the
Table I. Alopecia areata (AA) development with transferred cell type
Group
Cell type
(number injected)
Mice with
alopecia
localized at
the injection
site
Mice with
systemic AA
expression
after 20 wk
Conﬁdence
interval
(according
to Wilson)
Systemic AA
expression p-value
(compared with
1, non-AA)
Systemic AA
expression
p-value
(compared
with
1a, AA)
Systemic AA
expression
p-value
(group:group
comparison)
1 LNC non-AAa (1  107) 0/20 (0%) 0/20 (0%) (0%–10%)
1a LNC AAb (1  107) 8/10 (80%) 8/10 (80%) (49%–94%) o0.0001
2 CD8þ (1  107) 10/10 (100%) 1/10 (10%) (0.5%–40%) 0.33 0.006
3 CD4þ (1  107) 0/10 (0%) 3/10 (30%) (11%–60%) 0.03 0.07
4 CD4þ /CD25 (2  107) 4/23 (17%) 10/23 (43%) (26%–63%) 0.0007 0.07
5 CD4þ /CD25þ (1  107) 0/12 (0%) 2/12 (17%) (5%–45%) 0.13 0.008
6 CD11cþ (1  107) 0/9 (0%) 0/9 (0%) (0%–30%) 1.00 0.0007
7 CD19þ (2  107) 0/8 (0%) 0/8 (0%) (0%–30%) 1.00 0.001
8 CD8þ (2  107),
CD4þ /CD25þ (1  107)
5/5 (100%) 0/5 (0%) (0%–43%) (2:8) 1.00
9 CD4þ /CD25 (2  107),
CD4þ /CD25þ (1  107)
0/10 (0%) 0/10 (0%) (0%–28%) (4:9) 0.0148
10 CD4þ /CD25 (2  107),
CD8þ (1  107)
5/8 (63%) 5/8 (63%) (31%–86%) (2:10) 0.0040
(4:10) 0.40
aMice injected with LNC from normal haired donors.
bMice injected with LNC from AA-affected donors.
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treatment of chronic inflammatory disease (Horwitz et al,
2002; Lee et al, 2003). Although still very much a theoretical
option, the studies here suggest that the promotion of
CD4þ /CD25þ cells may be beneficial overall to treating AA.
Alopecia development after cell injection is associated
with increased skin lymphocyte cell inﬁltration Histolo-
gy and immunohistology of CD8þ cell-injected mice re-
vealed a local infiltrate at the site of injection largely
comprised of CD8þ cells (not shown). The CD8þ cells
had a focal peri- and intra-follicular infiltration presentation.
Affected hair follicles were in dystrophic anagen or in telo-
gen. In CD8þ cell-injected mice, the skin beyond the in-
jection site presented with a low level CD4þ and CD8þ cell
infiltration. While the lymphocytes were hair follicle focused,
the cells’ position was exclusively peri-follicular. Immuno-
histology of mice receiving CD4þ cells and developing alo-
pecia revealed a focal follicular infiltrate of lymphocytes
typical of that observed in spontaneous and skin graft-in-
duced mouse AA (McElwee et al, 1998, 2002; Zo¨ller et al,
2002) with CD4þ cells exclusively in a peri-follicular location
and CD8þ cells in both peri- and intra-follicular locations
(not shown).
Quantification of the number of cells extracted from the
skin at necropsy prior to flow cytometry analysis demon-
strated that all cell-injected mice had more cells extracted
as compared with control, non-injected mice regardless of
whether the mice developed AA (Fig 2a). Comparison of
mice that developed alopecia with those that failed to de-
velop AA within respective mouse groups injected with the
same cell type, however, showed that greater numbers of
cells were retrieved from those with overt hair loss. An in-
creased number of draining LNC were only recovered from
mice that developed AA (Fig 2b). Interestingly, all mice that
developed AA displayed an increased percentage of CD4þ
skin-infiltrating leukocytes (SkIL), independent of whether
the mice received CD4þ cell injections (Fig 2c). In fact, the
highest percentage of CD4þ cells was seen in mice devel-
oping localized AA after the transfer of CD8þ cells. It is
possible that through hair follicle destruction a strong, but
AA-independent, inflammatory response was induced. The
same phenomenon, although less pronounced, may ac-
count for the percentage of CD8þ cells. No increase in the
percentage of CD4þ or CD8þ cells was seen in mice that
did not develop AA (Fig 2c). In mice developing AA, there
was a decrease in the percentage of B cells and of mon-
ocytes (data not shown). Considering the increased number
of recovered SkIL in AA mice and the increased percentage
of CD4þ and CD8þ cells within the recovered SkIL pop-
ulation, the reduction in B cells and monocytes appeared to
be relative.
Alopecia development is associated with increased CD44
variant, pro-inﬂammatory cytokine, and co-stimula-
tory ligand activation but localized alopecia is associ-
ated with depressed co-stimulatory ligand expres-
sion CD44 variants, particularly CD44v3 and CD44v10,
Figure1
Localized and systemic hair loss with injection of CD8þ and CD4þ
cell combinations. Twenty weeks after injection of CD8þ cells, recipient
mice exhibited localized hair loss only at the site of injection (a). In con-
trast, injection of CD4þ /CD25 cells alone resulted in minimal alopecia
at the site of injection, but systemic alopecia developed in a subset and
was extensive by 20 wk postinjection (b). Combined injection of CD8þ
cells plus CD4þ /CD25þ cells yielded localized hair loss but to a much
more limited extent (c) whereas combination of CD4þ /CD25 plus
CD4þ /CD25þ cells resulted in no overt hair loss induction (d).
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have been described as skin-homing receptors (Ro¨sel et al,
1997; Seiter et al, 1999). The percentage of panCD44þ SkIL
was increased in mice developing localized or systemic AA,
primarily because of CD44v3 and CD44v10 expression,
consistent with the supposed skin-homing function of these
CD44 variant isoforms. The activation marker CD44v6 was
upregulated primarily in mice receiving CD4þ cells, irre-
spective of whether or not they developed AA, and CD44v7
expression was only increased in mice that received CD4þ
cells and developed AA (Fig 3). Although the latter finding is
in line with apoptosis resistance induction by CD44v7 (Mar-
haba et al, 2003 and see below), the strong upregulation of
CD44v6 in mice receiving CD4þ cells, but not developing
AA, indicates that cell transfer-induced AA development
may also be determined by regulatory phenomena.
Cytokines have repeatedly been described as contribut-
ing to AA development, although no clear Th1 or Th2 profile
has emerged (Hoffmann, 1999; McElwee et al, 2002). After T
cell transfer, there was a strong upregulation of IL-6, tumor
necrosis factor (TNF)a, IL-12, and interferon (IFN)g expres-
sion in mice developing localized or systemic AA. These
indicators reconfirm the activated status of SkIL. But IL-6
and IFNg expression were also increased, although to a
minor degree, in mice receiving CD4þ /CD25þ cells that did
not develop AA. These mice also displayed very high-level
expression of IL-10. CD4þ /CD25þ cells are known largely
not to secrete cytokines with the exception of IL-10 and
transforming growth factor b at a low level (Shevach, 2002;
Nakamura et al, 2004), however, they can infectiously in-
duce IL-10 expression (Jonuleit et al, 2002; Stassen et al,
2004). Our findings strongly suggest that the prevention of
AA development after the transfer/co-transfer of CD4þ /
CD25þ cells at least partly relies on the high-level regula-
tory IL-10 cytokine expression (Fig 4).
Of cell co-stimulatory ligands, CD40, CD80, and CD86
were found with increased frequency on SkIL from mice
with systemic AA, whereas mice with CD8þ cell-induced
localized AA presented with a slightly reduced expression
frequency for CD40 and CD86, and significantly so for CD80
(Fig 5). This failure in co-stimulatory ligand expression may
Figure 2
Increased cell numbers extracted from alopecia areata (AA)-affected mice and increase in the percentage of CD4þ and CD8þ lymph-
ocytes. Although all cell-injected mice had greater numbers of skin-infiltrating leukocytes extracted from their skin compared with non-injected
mice, leukocytes were retrieved in greater numbers from mice that developed localized or systemic alopecia as compared with mice that failed to
develop alopecia (a). In contrast, a strongly increased number of draining LNC was only recovered from mice that developed systemic AA (b).
Furthermore, a significant increase in the percentage of CD4þ and CD8þ skin-infiltrating leukocytes (SkIL) was seen in all mice developing localized
or systemic AA, but not in mice that did not develop AA. When mice received CD8þ or CD4þ /CD25 plus CD4þ /CD25þ cells, the relative
percentage of CD4þ cells was significantly decreased (c). MeanþSD values of three independently performed assays are shown. Significant
differences (po0.01) are indicated by an asterisk.
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be one explanation for the lack of systemic AA development
despite the apparent increased presence of CD4þ cells in
the SkIL population after CD8þ cell injection. The dynamics
of this successful localized alopecia induction, and its rel-
ative failure to induce systemic AA, is not defined in this
study. In other autoimmune disease models, however,
CD8þ cells have been defined as both regulators (Kado-
waki et al, 1994) and promoters (Huseby et al, 2001) of
disease pathogenesis suggesting potential functional
heterogeneity in this population. It is possible that there
are CD8þ regulatory cells among the injected cell popula-
tion. Although activated, pathogenic CD8þ cells may pro-
mote alopecia localized at the site of injection, it is possible
that a second regulatory CD8þ cell population may be ac-
tively involved in systemic damage limitation. Notably, too,
CD40, CD80, and CD86 expression was upregulated in
mice receiving CD8þ or CD4þ /CD25 cells together with
CD4þ /CD25þ cells, although these mice did not develop
AA. In addition to evidence of IL-10 secretion, this is more
evidence that the failure to develop AA may not be solely
because of a lack of activation, but may also be sustained
by a counter-regulation of response.
CD4þ /CD25þ /CD152þ regulatory cells are depressed in
numbers relative to pathogenic CD4þ /CD25þ /CD154þ
cells in mice that developed AA The importance of reg-
ulatory phenomena was further supported by the explora-
tion of the ratio of regulatory versus activated Th cells in the
skin of transferred mice. Examination of the CD4þ /CD25þ
population for an activated (CD154þ , also named CD40L)
versus regulatory (CD152þ , also named CTLA4) phenotype
demonstrated a greater ratio of CD4þ /CD25þ /CD154þ
cells to CD4þ /CD25þ /CD152þ cells in mice that devel-
oped AA. In direct contrast, mice with failed alopecia
induction presented with a greater ratio of regulatory phe-
notype CD4þ /CD25þ /CD152þ cells. These patterns dis-
appeared after in vitro stimulation (Fig 6). The presence of
CD154þ cells in the CD4þ /CD25þ cell population provides
further evidence in support of the explanation as to why two
mice developed AA after receiving CD4þ /CD25þ cells. Al-
though this population is strongly enriched for cells with a
regulatory phenotype, some cells may be recently activat-
ed, pathogenic cells. Overall, however, the regulatory cell
phenotype defined by CD4þ /CD25þ expression is impor-
tant in AA susceptibility. While injection of these cells can
help prevent AA transfer, their loss in the initiation of AA may
be a significant factor in disease perpetuation.
AA development is associated with an increase in le-
ukocyte cell resistance to apoptosis In addition to
immunosuppressive cytokines and regulatory T cells, acti-
vation-induced cell death (AICD) is the third regulatory el-
ement by which undue activation of the immune system is
avoided (Lenardo et al, 1999). Autoimmune diseases are
frequently associated with defects in pro-apoptotic mole-
cules or overexpression of anti-apoptotic molecules. We
asked whether apoptosis susceptibility and expression of
pro-apoptotic molecules might correlate with cell transfer-
induced AA. Apoptosis susceptibility was evaluated by An-
nexin V staining. Annexin V has high affinity for phospha-
tidylserine, which is normally only expressed on the inner
plasma membrane leaflet of healthy cells, but becomes ex-
ternalized in early apoptosis (Martin et al, 1995; Vermes
et al, 1995). Annexin V binding was reduced in SkIL from
Figure 3
Skin-homing receptors are expressed with increased frequency on skin-infiltrating leukocytes from alopecia-affected mice. Mice with
localized or systemic alopecia development revealed skin-infiltrating leukocyte populations with increased expression of skin-homing receptors
CD44v3 and CD44v10. The activation marker CD44v6 was particularly high after the transfer of CD4þ cells and independent of systemic alopecia
areata (AA) induction. Upregulation of CD44v7 expression was only seen in AA mice after the transfer of CD4þ cells. MeanþSD values of three
independently performed assays are shown. Significant differences (po0.01) are indicated by an asterisk.
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Figure 4
Increased pro-inflammatory cytokine expression in skin-infiltrating leukocytes with alopecia development. Mice with alopecia development
exhibited increased frequencies of inflammatory leukocytes expressing interleukin (IL)-12, interferon (IFN)g, IL-6, and tumor necrosis factor (TNF)a.
With the exception of mice receiving CD4þ cells, IL-10 expression was high in mice not developing alopecia areata (AA) and was further increased in
mice receiving mixtures of lymphocytes including CD4þ /CD25þ cells. MeanþSD values of three independently performed assays are shown.
Significant differences (po0.01) are indicated by an asterisk.
Figure 5
Alopecia development is associated with upregulation of costimulatory ligands. The skin-infiltrating leukocyte population from systemic
alopecia-affected mice contained more cells with CD40, CD80, and CD86 expression. But costimulatory molecule expression was also high in mice
that received mixtures of CD8þ or CD4þ /CD25 and CD4þ /CD25þ cells. Leukocytes from CD8þ cell-injected mice presented with reduced
expression, particularly of CD80. MeanþSD values of three independently performed assays are shown. Significant differences (po0.01) are
indicated by an asterisk.
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AA-affected mice indicating reduced responsiveness to
apoptosis-inducing mechanisms and cellular resistance to
apoptosis in the SkIL population (Fig 7). Annexin V staining
was also reduced, although less pronounced, in mice re-
ceiving CD4þ /CD25 plus CD4þ /CD25þ cells, indicating
that AA resistance in these mice may not be because of
resistance towards AICD.
CD95 (Fas) and CD95L (FasL) and liganding of CD120a
(TNF receptor 1) and CD120b (TNF receptor 2) via TNFa or
LTa/LTb binding, respectively (Wallach et al, 1999; Schmitz
et al, 2000), are the most prominent death-inducing recep-
tor/ligand pairs. CD95L in particular is constitutively ex-
pressed at a higher level in SkIL than other lymphoid
organs.1 Examination of SkIL for apoptosis promoting mark-
ers revealed significantly decreased expression of CD95,
CD95L, CD120a, and CD120b in mice that developed AA.
Notably, CD120a and CD95L expression were upregulated
in mice that did not develop AA after receiving CD4þ /CD25
cells (Fig 7). This apparent reduced leukocyte susceptibility
to AICD via reduced CD95–CD95L and CD120 expression
may additionally support AA perpetuation. This may explain
the observed response to the transfer of CD4þ /CD25 cells
in particular, as in these mice, not only was downregulation
of death receptors seen in AA but also upregulation of death
receptors in mice that did not develop AA.
Summary Although in vitro activation of cells prior to trans-
fer is sometimes required in other autoimmune disease
models (Braley-Mullen et al, 1985; Clark and Lingenheld,
1998; Gilhar et al, 1998), in this study in vitro stimulation was
not necessary and the cells retained their apparent in vivo
conditioned properties throughout the cell separation proc-
ess. Not using in vitro stimulation avoids promoting prolif-
eration of cell clones that may not be fundamentally
involved in the in vivo disease state. The study also dem-
onstrates that normal mouse pelage hair follicles, not pre-
viously exposed to AA mechanisms, can be targeted by
in vivo primed immune cells. The CD4þ /CD25 cell pop-
ulation in the C3H/HeJ mouse model retains the capacity to
transfer the systemic AA phenotype to naive hosts and most
likely promotes AA via promotion of APC activity and sub-
sequent stimulation of hair follicle autoreactive CD8þ cells.
This pathogenic activity defines the CD4þ /CD25 cell pop-
ulation as a key component of AA and a prime target for the
development of therapeutic strategies. Understanding the
mechanisms of which CD4þ /CD25 cells interact with APC
in AA and which specific CD4þ /CD25 cell clones are truly
pathogenic will provide new insights into AA pathogenesis.
The CD4þ /CD25þ cell population has been confirmed as
functionally a predominantly regulatory cell subset in AA.
Boosting regulatory cell activity may be one method of
counteracting CD4þ /CD25 pathogenicity.
Materials and Methods
Mice All procedures were approved by the regional animal ethics
committee and in accordance with state guidelines. C3H/HeJ mice
(The Jackson Laboratory, Bar Harbor, Maine) received autoclaved
food pellets (altromin 1434, Altromin GmBH, Lage, Germany) and
acidified water (pH 2.8–3.0) ad libitum. Twenty normal haired fe-
male mice (control) and 150þ female, AA-affected mice, produced
by grafting skin from spontaneously AA-affected mice to normal
haired recipients as previously described (McElwee et al, 1998),
were used as cell donors. All recipients were females and allotted
to age-matched groups of 10–20 wk.
Figure 6
Alopecia areata (AA) is associated with greater numbers of pathogenic CD4þ /CD25þ /CD154þ cells. The ratio of candidate pathogenic
CD4þ /CD25þ /CD154þ cells to regulatory CD4þ /CD25þ /CD152þ cells in both draining lymph nodes and skin was greater in AA-affected mice
with an up to twofold difference. Stimulation abrogated the distinction. Mean  SD of three independently performed assays is shown.
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Cell transfer Normal haired and AA-affected C3H/HeJ donor mice
were euthanized by cervical dislocation. Single cell suspensions
were prepared from pooled skin draining lymph nodes (axillary,
brachial, superficial cervical, inguinal) or, in the case of CD19þ
cells, spleens of AA-affected mice. For comparative controls, 20
mice were injected subcutaneously with unseparated lymph node
cells from normal haired donors and 10 mice received equivalent
cell injections from AA-affected mice. Cell subsets were isolated
using antibody-conjugated magnetic particle separation (Radbruch
et al, 1994). Cells were selected ready for transfer-using combi-
nations of anti-CD19 (clone 1D3), CD4 (clone GK1.5), CD8a (clone
53–6.7), and CD11c (clone N418) mAb (All Miltenyi, Bergisch Glad-
bach, Germany) and manufacturer’s standard protocols. CD4þ /
25þ and CD4þ /CD25 cells were isolated by non-T cell depletion
followed by anti-CD25-phycoerythrin (PE) (clone 7D4) and anti-PE
magnetic particles. Positive selection does not induce activation in
the selected cells (Nohe et al, 2002). Recipients’ injected cell
combinations and cell numbers are listed in Table I. Confidence
intervals for systemic AA expression in the different mouse groups
were calculated according to Wilson’s method (Newcombe, 1998).
Statistical analyses of systemic AA frequencies in different groups
were performed with Fisher’s exact test (Agresti et al, 1990).
Flow cytometry For in vitro stimulation assays and flow cytometry
analyses, the entire dorsal and ventral skin and draining lymph
nodes were collected at necropsy 20 wk after cell injection. Single
leukocyte cell suspensions were prepared from the skin as pre-
viously described (Zo¨ller et al, 2002). SkIL from two to three an-
imals were pooled. Viability was determined by Trypan blue
exclusion and was in the range of 70%–80% in SkIL preparations.
Each cell sample was aliquoted and incubated with 10 mg per mL
of the primary antibody and subsequently with the appropriate
anti-mouse or anti-rat PE-labeled secondary antibody, or after in-
cubating with biotinylated mAb, with streptavidin PE. Negative
controls were incubated with a non-binding primary antibody
and the same secondary reagents. For intra-cellular labeling of
cytokines, cells were fixed and permeabilized in advance. For
double fluorescence analysis, cells were first labeled with a bio-
tinylated antibody and Streptavidin PE followed by exposure to
the second, fluorescein isothiocyanate (FITC)-labeled antibody.
Annexin V (1 mg per mL) and propidium iodide (PI) (1 mg per mL)
staining was performed in binding buffer (10 mM HEPES/NaOH,
pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). Flow cytometry (FACSstar,
Becton Dickinson, Heidelberg, Germany) followed routine proce-
dures (Zo¨ller et al, 2002). Cell viability was assessed by PI exclu-
sion and cell debris and dead cells were excluded from analysis. All
experiments were repeated at least three times. Values represent
the mean and, where indicated, the standard deviation (SD). The
significance of differences was evaluated using the two-tailed Stu-
dent’s T test.
Antibodies The following mAb were used for flow cytometry:
biotinylated anti-mouse IL-6 (clone MP5-32C11), IL-10 (clone JES3-
16E3), IL-12 (clone C17.8), IFNg (clone XMG1.2), TNFa (clone MP6-
XT3); unconjugated or FITC- or PE-conjugated anti-mouse CD25
(clone PC61), CD40 (clone 3/23), CD80 (clone 16-10A1), CD86 (clone
GL1), CD152 (CTLA-4, clone 1B8), CD154 (CD40L, clone MR1), and
sIgM (clone R6-60.2); anti-CD95 (clone Jo2), CD95L (clone MFL3),
CD120a (clone 55R-286), and CD120b (clone TR75-89) (all BD/Phar-
mingen, Hamburg, Germany); anti-CD44v6 (clone 9A4, BenderMed
Systems, Vienna, Austria), rabbit anti-CD44v7 (Chemicon Interna-
tional, Temeccula, California), anti-mouse CD4 (clone YTA 3.2.1),
CD8 (clone YTS 169.4.2.1), and monocyte/macrophage (clone YBM
6.6.10) (European Animal Cell Culture Collection, Porton Down, UK);
anti-panCD44 (clone IM7) (American Type Culture Collection, Man-
assus, Virginia); unconjugated or biotinylated anti-CD44v3 (clone
PTS33, Seiter et al, 1999), and anti-CD44v10 (clone K926, Ro¨sel
et al, 1997); biotinylated secondary reagents, PE- and FITC-labeled
anti-rat IgG, anti-mouse IgG, anti-rabbit IgG, anti-hamster IgG, and
Streptavidin (all Dianova, Hamburg, Germany).
Cell stimulation assay Cytokine and co-stimulatory molecule ex-
pression was tested by flow cytometry after overnight culture of
SkIL in the presence of 1 mg per mL PHA. Apoptosis susceptibility
(Annexin V staining) was evaluated after overnight culture on plates
coated with subthreshold levels of anti-CD3 (1 mg per mL) that is
Figure 7
Increased leukocyte resistance to apoptosis in alopecia areata (AA)-affected mice. Skin-infiltrating leukocytes from mice with either localized
or systemic alopecia demonstrated reduced expression of CD95, CD95L, CD120a, and CD120b. This reduction in receptors associated with
activation-induced cell death was associated with reduced annexin V binding, an indicator of apoptosis susceptibility. MeanþSD values of three
independently performed assays are shown. Significant differences (po0.01) are indicated by an asterisk.
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known to drive leukocytes into apoptosis. Cell subpopulations
(CD4þ /CD25þ /CD152þ or CD4þ /CD25þ /CD154þ ) were stimu-
lated by seeding in triplicate on anti-CD3-coated flat-bottom 24-
well plates (10 mg per mL) and adding 10 mg per mL anti-CD28 to
the culture medium. The number of cells was kept constant
(1  105 cells per well), but the stimulant was titrated from 10 to
1.25 mg per mL. Cells in microtiter plates were cultured for 16–48 h.
Cells were harvested, centrifuged, adjusted to 1–5  105/100 mL
and 100 mL aliquots were transferred into 96-well plates for flow
cytometry.
Histology and immunohistology At necropsy, ventral skin sam-
ples at the site of injection and dorsal skin were fixed in Fekete’s
acid–alcohol–formalin solution and paraffin embedded for routine
histology (Relyea et al, 1999). Skin samples were also embedded in
the OCT compound (Tissue tek, Sakura, Zoeterwoude, the Neth-
erlands) and snap frozen in liquid nitrogen for subsequent immuno-
histology as described elsewhere (Freyschmidt-Paul et al, 2000).
Primary antibodies were; anti-mouse CD4 (clone RM4-5, Phar-
mingen, San Diego, California) and CD8 (clone 53–6.7, Southern
Biotechnology, Birmingham, Alabama). Tissue sections were
counter-stained with Mayer’s hematoxylin. The primary antibody
was replaced with normal rat IgG for negative controls.
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